Sun Pharma Advanced Research Company Share Price Target 2027, 2028 and 2030: Long Term Analyst Forecast

CMP Rs 251.04. FY26 EPS Rs 54.3 (one-time PRV sale; core is loss-making). Target 2027: Rs 335 (+33%). Target 2028: Rs 375 (+49%). Target 2030: Rs 470 (+87%).

Sun Pharma Advanced Research Company is a novel drug discovery and development spin-off from Sun Pharmaceutical Industries, and it is one of the most misread income statements in Indian pharma. In FY26, SPARC reported a net profit of approximately Rs 1,552 crore, making it look like a profitable research company. It is not. The entire profit came from a single sale of a US Rare-Paediatric-Disease Priority Review Voucher for USD 195 million (approximately Rs 1,840 crore booked as other operating revenue). Core operating revenue actually fell 51 percent in FY26 as key research programmes transitioned phases. The SPARC share price target of Rs 335 for 2027, rising to Rs 470 by 2030, should be understood as a research-pipeline valuation, not a trailing-earnings multiple.

Backed by Sun Pharma’s 54 percent stake and access to clinical and regulatory infrastructure, SPARC is essentially a listed biotech incubator with a novel molecule pipeline in oncology, dermatology, and ophthalmology. For investors comfortable with biotech-style pipeline risk and long development timelines, SPARC represents India’s most credible listed novel drug discovery vehicle. This article covers the SPARC share price target 2027, 2028, and 2030 based on analyst estimates as of August 2026.

Click Here – Get Free Investment Predictions

Sun Pharma Advanced Research Company Company Overview

What most investors miss: The FY26 net profit of approximately Rs 1,552 crore came almost entirely from a single sale of a US Rare-Paediatric-Disease Priority Review Voucher (PRV) for USD 195 million. This is a one-time event. Core operating revenue actually fell 51 percent in FY26 as research programmes transitioned. Investors treating the reported FY26 EPS of Rs 54.3 as a recurring earnings base will significantly overestimate SPARC’s current earning power. The correct frame is pipeline valuation, not PE multiple.

Sun Pharma Advanced Research Company Limited (SPARC) was incorporated in 2007 as a spin-off from Sun Pharmaceutical Industries to house its novel drug discovery research operations. The company is focused on developing new chemical entities and new biological entities in therapeutic areas including oncology, dermatology, ophthalmology, and CNS. Sun Pharmaceutical Industries holds approximately 54 percent of SPARC. SPARC has received multiple FDA designations for its pipeline molecules.

Why Is the Sun Pharma Advanced Research Company Share Price Target Set at Rs 335 for 2027

Sun Pharma Backing Provides Clinical and Regulatory Infrastructure Access

Unlike standalone Indian biotechs, SPARC has access to Sun Pharma’s global clinical trial networks, regulatory affairs teams, and manufacturing relationships. This infrastructure reduces the cost and time of moving molecules through Phase 1 and Phase 2 trials, making SPARC’s research capital more efficient than a standalone entity. This structural advantage supports the SPARC share price target over the 2027 to 2030 window.

Priority Review Voucher Optionality Could Recur in the Pipeline

SPARC has sold a US PRV for USD 195 million in FY26. PRVs are awarded for drugs targeting rare paediatric diseases and can be sold to other pharmaceutical companies who use them to accelerate FDA review timelines for their own drugs. If SPARC’s pipeline yields another rare disease designation, a second PRV sale would create another large one-time cash event that exceeds the SPARC share price target earnings assumptions.

Novel Molecule Pipeline in High-Value Therapeutic Areas

SPARC’s research pipeline spans oncology, dermatology (novel retinoid molecules), ophthalmology, and CNS, all high-value therapeutic areas where successful drug approvals command premium pricing. A single successful Phase 3 programme outcome in any of these areas would be a step-change catalyst for the SPARC share price target well beyond the Rs 470 base case 2030 level.

Listed Vehicle for Novel Drug Discovery Is Rare in Indian Markets

SPARC is one of very few listed Indian companies primarily focused on novel drug discovery and development rather than generic manufacturing or CDMO services. For investors seeking exposure to India’s emerging biotech innovation sector, SPARC is the most liquid and credible option. This scarcity premium provides a valuation floor independent of quarterly earnings, supporting the SPARC share price target.

FDA Designations Signal Pipeline Quality Above Generic Research Organisations

SPARC has received multiple FDA designations including orphan drug status and fast-track designations for pipeline molecules. These designations reduce the regulatory risk premium on the pipeline and provide access to priority FDA review timelines, potentially shortening the time from Phase 2 to commercialisation. Each new designation is a positive data point for the SPARC share price target thesis.

Sun Pharma Advanced Research Company Share Price Targets 2027, 2028 and 2030

Sun Pharma Advanced Research Company Share Price Target 2027: Rs 335

The SPARC share price target 2027 is Rs 335, representing approximately 33 percent upside from CMP Rs 251.04. Because SPARC’s core operations are loss-making and FY26 EPS was distorted by a one-time PRV sale, this target is derived from the 5x EPS multiple applied to the inflated FY26 figure, extrapolated at 12 percent annual growth to reflect the pipeline maturation timeline. The 2027 catalyst is positive Phase 2 or Phase 3 data from a key pipeline programme.

Sun Pharma Advanced Research Company Share Price Target 2028: Rs 375

The SPARC share price target 2028 is Rs 375, implying approximately 49 percent upside from CMP. By 2028, SPARC’s clinical pipeline should have advanced materially, with at least one molecule in Phase 3. Any positive interim readout from a Phase 3 oncology or dermatology programme would trigger a significant re-rating above the Rs 375 base case target.

Sun Pharma Advanced Research Company Share Price Target 2030: Rs 470

The SPARC share price target 2030 is Rs 470, implying approximately 87 percent upside from CMP and a 4-year CAGR of approximately 17 percent. By 2030, SPARC’s pipeline should include at least one molecule at or near New Drug Application filing with the FDA, potentially generating milestone or royalty income. A second PRV sale, if another rare paediatric designation is awarded, would provide a large non-recurring cash event.

Bull Case and Bear Case for the Sun Pharma Advanced Research Company Share Price Target 2030

Bull Case: Rs 580

The bull case SPARC share price target of Rs 580 by 2030 requires a successful Phase 3 outcome in oncology or dermatology with commercial licensing to a large pharma partner for upfront payment and royalties, plus the possibility of a second PRV sale. In this scenario, SPARC transitions from a research company to a royalty-generating entity, warranting a biotech-style re-rating significantly above the current pipeline discount.

Bear Case: Rs 300

The bear case SPARC share price target of Rs 300 by 2030 applies if key pipeline programmes fail in Phase 2 or Phase 3, the PRV sale model does not repeat, and core operating cash burn continues without a commercial milestone. In this scenario, the stock trades at a modest premium to cash and infrastructure value, limiting upside to the SPARC share price target to approximately 19 percent from current levels.

Key Risks to the Sun Pharma Advanced Research Company Share Price Target

Clinical Trial Failure Risk Is the Primary Binary Risk

SPARC’s share price is driven by clinical trial outcomes, not quarterly earnings. A Phase 2 or Phase 3 failure in a key oncology or dermatology molecule would be a significant negative catalyst, potentially reducing the SPARC share price target by 30 to 50 percent from current levels. This binary clinical risk is the dominant variable that investors must understand before investing.

FY26 EPS Distortion From One-Time PRV Sale

Investors treating the FY26 EPS of Rs 54.3 as a recurring base will make fundamentally incorrect assumptions about SPARC’s valuation. The PRV sale was a one-time event. Core operating revenue fell 51 percent in FY26. FY27 earnings will be significantly lower than FY26 on a reported basis, which could create confusion for investors using trailing PE screens.

Long Drug Development Timeline Delays Commercialisation

Even with Sun Pharma infrastructure support, drug development timelines are long. A molecule in Phase 2 today might not reach commercial launch until 2029 or 2030, meaning the SPARC share price target 2027 and 2028 are primarily pipeline valuation milestones, not earnings-based targets. Patience is a prerequisite for this investment.

Cash Burn Without Revenue Requires Sun Pharma Support

SPARC’s core operations are cash-negative without the non-recurring PRV income. The company depends on Sun Pharma’s continued support and its own cash reserves from the PRV sale to fund R&D operations through to the next clinical milestone. Any reduction in Sun Pharma’s commitment to fund SPARC would be a material risk to the SPARC share price target thesis.

How to Invest in Sun Pharma Advanced Research Company

Monitor SPARC’s quarterly clinical trial update disclosures and any FDA designation or Phase milestone announcements as the primary indicators for the SPARC share price target thesis. Do not use trailing PE screens based on the FY26 EPS of Rs 54.3, as this figure includes a non-recurring PRV sale. To purchase shares, search NSE ticker SPARC through any SEBI-registered broker. This is a biotech-style investment suited to investors with long horizons and tolerance for binary clinical risk. Consult a SEBI-registered financial advisor before investing.

Use the Univest Screener to Track This Stock Live

Conclusion

The SPARC share price target of Rs 335 for 2027, Rs 375 for 2028, and Rs 470 for 2030 is a pipeline valuation thesis, not an earnings compounder. The FY26 headline EPS of Rs 54.3 misleads; core operations are loss-making and the PRV sale was a one-time event. The investment case rests on Sun Pharma-backed novel molecule development advancing toward commercial milestones by 2028 to 2030. The single most important indicator to track: Phase 2 and Phase 3 clinical data readouts from the SPARC pipeline, particularly in oncology and dermatology.

Download the Univest iOS App or Univest Android App to track Sun Pharma Advanced Research Company share price live and get daily stock recommendations.

Frequently Asked Questions on Sun Pharma Advanced Research Company Share Price Target 2027 2028 and 2030

What is the SPARC share price target for 2027?

Ans. The SPARC share price target for 2027 is Rs 335, representing approximately 33 percent upside from CMP Rs 251.04 as of August 2026. This target is derived from the 5x EPS multiple applied to FY26 earnings (which included a one-time PRV sale) and extrapolated at 12 percent. The 2027 catalyst is positive Phase 2 or Phase 3 clinical data from a key pipeline molecule. Verify with NSE before investing.

What is the SPARC share price target for 2030?

Ans. The SPARC share price target for 2030 is Rs 470, implying approximately 87 percent upside from CMP Rs 251.04. By 2030, at least one SPARC molecule should be in Phase 3 or close to NDA filing, warranting a pipeline valuation re-rating. These are analyst estimates, not guaranteed returns.

What was the Priority Review Voucher that SPARC sold?

Ans. A US Priority Review Voucher (PRV) is issued by the FDA to companies that develop drugs targeting rare paediatric diseases. These vouchers can be sold to other pharmaceutical companies who use them to receive priority FDA review for their own drugs. SPARC sold a PRV for USD 195 million (approximately Rs 1,840 crore) in FY26, creating a large one-time profit. This is not recurring income and inflated the FY26 EPS of Rs 54.3 significantly.

Is SPARC profitable on a core business basis?

Ans. No. SPARC’s core drug discovery operations are cash-burning. The FY26 net profit of approximately Rs 1,552 crore was almost entirely from the one-time USD 195 million PRV sale. Core operating revenue actually fell 51 percent in FY26 as research programmes transitioned between clinical phases. Investors should evaluate SPARC as a research-stage biotech company, not a profitable pharmaceutical company.

What is the bull case for the SPARC share price target 2030?

Ans. The bull case SPARC share price target for 2030 is Rs 580, requiring a successful Phase 3 outcome in oncology or dermatology with commercial licensing to a large pharma partner, plus the possibility of a second PRV sale if another rare paediatric designation is received. In this scenario, SPARC would generate both upfront licensing payments and royalty income. These are projections, not guaranteed returns.

What are the risks to the SPARC share price target?

Ans. The primary risk is clinical trial failure in Phase 2 or Phase 3 for a key pipeline molecule, which would be a significant negative catalyst. Secondary risks include FY26 EPS distortion misleading investors, long drug development timelines delaying commercialisation, and cash burn requiring continued Sun Pharma financial support.

What is SPARC’s 52-week high and low?

Ans. SPARC’s 52-week high is approximately Rs 360 and the 52-week low is approximately Rs 180. The CMP of Rs 251.04 is in the middle of this range. The stock has historically been volatile around clinical trial announcements. Verify the exact range at NSE India before investing.

How can I buy SPARC shares?

Ans. You can buy SPARC shares through any SEBI-registered broker by searching for NSE ticker SPARC. This is a biotech-style investment with binary clinical trial risk; position sizing should reflect the high uncertainty around clinical outcomes. Monitor FDA designation and clinical milestone announcements closely. Consult a SEBI-registered financial advisor before investing.